Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 4/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL307359 | 0.80 | — | — | |
| Sulfuric Acid SCHEMBL18584 | 0.80 | BLM (0.47) | BLMKDM4ECA5ACA5BNPSR1 | |
| Sulfuric Acid SCHEMBL1940141 | 0.80 | BLM (0.47) | BLMKDM4ECA5ACA5BNPSR1 | |
| Sulfuric Acid SCHEMBL3892286 | 0.80 | BLM (0.47) | BLMKDM4ECA5ACA5BNPSR1 | |
| Pimagedine SCHEMBL439904 | 0.77 | BLM (1.00) | BLMKDM4ECA5ACA5BNPSR1 | |
| Pimagedine SCHEMBL5968075 | 0.77 | BLM (1.00) | BLMKDM4ECA5ACA5BNPSR1 | |
| Bromide SCHEMBL11505136 | 0.76 | — | — | |
| Water SCHEMBL1971739 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL526048 | 0.76 | — | — | |
| Hydroxyguanidine SCHEMBL961747 | 0.74 | BLM (0.67) | BLMKDM4ECA5ACA5BNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4247632-A | QUANTITATIVE ANALYSIS OF METHYLAMINE AND UREA PRODUCTS; CULTURES USING ALCALIGENES | KIKKOMAN SHOYU CO., LTD. (JP) | 1981-01-27 | — | — | US | claimed |
| US-20240218344-A1 | LIQUID THROMBIN REAGENT | INSTRUMENTATION LABORATORY COMPANY | 2024-07-04 | — | — | US | disclosed |
| EP-4389140-A1 | LIQUID THROMBIN REAGENT CONTAINING GUANIDINE DERIVATIVES | Instrumentation Laboratory Company (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-114072378-A | Process for preparing metastable crystal modifications of N- (aminoiminomethyl) -2-aminoacetic acid (III) | 澳泽化学特罗斯特贝格有限公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-101190897-B | Method for synthesizing 4-(4-fluorophenyl)-6-isopropyl-2-methylaminopyrimidine-5-formic acid ester | TIANJIN TASLY GROUP CO LTD | 2011-05-11 | — | — | CN | disclosed |
| CN-101190897-A | Method for synthesizing 4-(4-fluorophenyl)-6-isopropyl-2-methylaminopyrimidine-5-formic acid ester | TIANJIN TASLY GROUP CO LTD (CN) | 2008-06-04 | — | — | CN | disclosed |
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | KYOWA HAKKO KOGYO CO.,LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1726584-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
| EP-0217787-A4 | AMIDINOUREA PROCESS AND PHARMACEUTICAL COMPOSITION. | RORER INTERNAT OVERSEAS INC (US) | 1988-07-21 | — | — | EP | disclosed |
| EP-0217787-A1 | AMIDINOUREA PROCESS AND PHARMACEUTICAL COMPOSITION | RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) (US) | 1987-04-15 | — | — | EP | disclosed |
| US-4503147-A | CULTURE PRODUCT OF BACILLUS | KIKKOMAN CORPORATION (JP) | 1985-03-05 | — | — | US | disclosed |
| EP-0116639-A1 | ACYL GUANIDINES | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1984-08-29 | — | — | EP | disclosed |
| WO-1984000875-A1 | ACYL GUANIDINES | RORER INT OVERSEAS (US) | 1984-03-15 | — | — | WO | disclosed |
| US-4418209-A | ANTIULCER, ANTIARRYTHMIC, ANTIDIARRHEAL, ANTISPASMODIC, ANTIPARASITIC, AND ANTISECRETORY AGENTS | WILLIAM H. RORER, INC. (US) | 1983-11-29 | — | — | US | disclosed |
| EP-0079377-A1 | HETEROCYCLIC ALKYLENE AMIDINOUREAS | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1983-05-25 | — | — | EP | disclosed |
| WO-1982004048-A1 | HETEROCYCLIC ALKYLENE AMIDINOUREAS | RORER INT OVERSEAS (US) | 1982-11-25 | — | — | WO | disclosed |
| US-4247632-A | QUANTITATIVE ANALYSIS OF METHYLAMINE AND UREA PRODUCTS; CULTURES USING ALCALIGENES | KIKKOMAN SHOYU CO., LTD. (JP) | 1981-01-27 | — | — | US | disclosed |
| US-4178387-A | ADMINISTERING AMIDINOUREAS | WILLIAM H. RORER, INC. (US) | 1979-12-11 | — | — | US | disclosed |
| US-4147804-A | ANTIARRHYTHMIA AGENTS | WILLIAM H. RORER, INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4085211-A | DIURETICS, NATRIURETICS | MERCK & CO., INC. (US) | 1978-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | AGTR2, ABL1, AGTR1 | BLM 2208/4885KDM4E 1708/4885CA5A 2353/4885 |
| US-20240218344-A1 | LIQUID THROMBIN REAGENT | TFPI, F2, PLG | BLM 1567/4885KDM4E 600/4885CA5A 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.